Abstract:Multiple sclerosis (MS), a prevalent neurological disorder, predominantly affects young adults and is characterized by chronic autoimmune activity. The study explores the immune system dysregulation in MS, highlighting the crucial roles of immune and non-neuronal cells in the disease's progression. This review examines the dual role of cytokines, with some like IL-6, TNF-α, and interferon-gamma (IFN-γ) promoting inflammation and CNS tissue injury, and others such as IL-4, IL-10, IL-37, and TGF-β fostering remyelination and protecting against MS. Elevated chemokine levels in the cerebrospinal fluid (CSF), including CCL2, CCL5, CXCL10, CXCL13, and fractalkine, are analyzed for their role in facilitating immune cell migration across the blood-brain barrier (BBB), worsening inflammation and neurodegeneration. The study also delves into the impact of auto-antibodies targeting myelin components like MOG and AQP4, which activate complement cascades leading to further myelin destruction. The article discusses how compromised BBB integrity allows immune cells and inflammatory mediators to infiltrate the CNS, intensifying MS symptoms. It also examines the involvement of astrocytes, microglia, and oligodendrocytes in the disease's progression. Additionally, the effectiveness of immunomodulatory drugs such as IFN-β and CD20-targeting monoclonal antibodies (e.g., rituximab) in modulating immune responses is reviewed, highlighting their potential to reduce relapse rates and delaying MS progression. These insights emphasize the importance of immune system dysfunction in MS development and progression, guiding the development of new therapeutic strategies. The study underscores recent advancements in understanding MS's molecular pathways, opening avenues for more targeted and effective treatments.

The role of fibronectin in multiple sclerosis and the effect of drug delivery across the blood-brain barrier

Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis

The Blood–Brain Barrier—A Key Player in Multiple Sclerosis Disease Mechanisms

Brain Barriers and Multiple Sclerosis: Novel Treatment Approaches from a Brain Barriers Perspective

FGF/FGFR system in the central nervous system demyelinating disease: Recent progress and implications for multiple sclerosis

Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics

[Mechanisms Underlying Remyelination with Special Focus on Demyelination Models of Multiple Sclerosis].

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis

An Ex-Vivo Multiple Sclerosis Model of Inflammatory Demyelination Using Hyperbranched Polymer

Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis

Immunomodulatory Therapies of Multiple Sclerosis

Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets

The remyelination effect of DNA framework nucleic acids on demyelinating diseases

Restoring immune suppression in the multiple sclerosis brain

Infiltration by monocytes of the central nervous system and its role in multiple sclerosis: reflections on therapeutic strategies

New Insight into Brain Disease Therapy: Nanomedicines-Crossing Blood–brain Barrier and Extracellular Space for Drug Delivery

The role of microRNAs involved in the disorder of blood–brain barrier in the pathogenesis of multiple sclerosis

Nanosystems and exosomes as future approaches in treating multiple sclerosis

Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination

Microglia Regulate Blood–Brain Barrier Integrity via MiR‐126a‐5p/MMP9 Axis during Inflammatory Demyelination

Immune System Dysregulation in the Progression of Multiple Sclerosis: Molecular Insights and Therapeutic Implications